rhTPO improved hematopoietic reconstitution after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800017025

Enrollment

Unknown

Registered

2018-07-09

Start date

2014-03-01

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

2 Groups:start rhTPO from D1 versus D3

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. newly diagnosed multiple myeloma; 2. obtained >=PR response after receiving no more than 8 cycles of induction chemotherapy (PAD/VD regimen); 3. normal heart function, normal lung function, normal liver functin: bilirubin level no more than 35umol/L, AST/ALT less than 2 times of ULR.

Exclusion criteria

Exclusion criteria: 1. allergy to rhTPO; 2. had received myelosuppressive drugs including melphalan, lenalidomide; 3. with comobidities causing thrombocytopenia, including ITP, MDS etc.; 4. platelet counts less than 80*109/L before transplant; 5. complicated with thromboembolism diseases or had new thromboembolism events within 6 months not resulting from invention precedures; 6. heart function failure, EF< 50%; 7. dialysis dependent renal insufficiency.

Design outcomes

Primary

Measure	Time frame
hematopoietic recovery time;	—

Secondary

Measure	Time frame
Blood routine;	—

Countries

China

Contacts

Public ContactJuan Li

The First Affiliated Hospital of Sun Yat-sen University

13719209240@163.com+86 13719209240

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026